Skip to main navigation Skip to search Skip to main content

Genome-wide association study of prostate cancer-specific survival

  • Robert Szulkin
  • , Robert Karlsson
  • , Thomas Whitington
  • , Markus Aly
  • , Henrik Gronberg
  • , Rosalind A. Eeles
  • , Douglas F. Easton
  • , Zsofia Kote-Jarai
  • , Ali Amin Al Olama
  • , Sara Benlloch
  • , Kenneth Muir
  • , Graham G. Giles
  • , Melissa C. Southey
  • , Liesel M. Fitzgerald
  • , Brian E. Henderson
  • , Fredrick R. Schumacher
  • , Christopher A. Haiman
  • , Csilla Sipeky
  • , Teuvol J. Tammela
  • , Børge G. Nordestgaard
  • Timothy J. Key, Ruth C. Travis, David E. Neal, Jenny L. Donovan, Freddie C. Hamdy, Paul D.P. Pharoah, Nora Pashayan, Kay Tee Khaw, Janet L. Stanford, Stephen N. Thibodeau, Shannon K. McDonnell, Daniel J. Schaid, Christiane Maier, Walther Vogel, Manuel Luedeke, Kathleen Herkommer, Adam S. Kibel, Cezary Cybulski, Jan Lubinski, Wojciech Kluzniak, Lisa Cannon-Albright, Hermann Brenner, Volker Herrmann, Bernd Holleczek, Jong Y. Park, Thomas A. Sellers, Hui Yi Lim, Chavdar Slavov, Radka P. Kaneva, Vanio I. Mitev, Amanda Spurdle, Manuel R. Teixeira, Paula Paulo, Sofia Maia, Hardev Pandha, Agnieszka Michael, Andrzej Kierzek, Jyotsna Batra, Judith A. Clements, Demetrius Albanes, Gerald L. Andriole, Sonja I. Berndt, Stephen Chanock, Susan M. Gapstur, Edward L. Giovannucci, David J. Hunter, Peter Kraft, Loic Le Marchand, Jing Ma, Alison M. Mondul, Kathryn L. Penney, Meir J. Stampfer, Victoria L. Stevens, Stephanie J. Weinstein, Antonia Trichopoulou, Bas H. Bueno-De-mesquita, Anne Tjønneland, David G. Cox, Lovise Maehle, Johanna Schleutker, Sara Lindstrom, Fredrik Wiklund
  • Karolinska Institutet
  • Stockholm County Council
  • Institute of Cancer Research
  • The Royal Marsden NHS Foundation Trust
  • University of Cambridge
  • Faculty of Biology, Medicine and Health
  • Warwick Medical School
  • Cancer Council Victoria
  • Centre for Epidemiology and Biostatistics
  • University of Melbourne
  • University of Southern California
  • University of Turku and Turku University Hospital
  • Tampere University Hospital
  • Gentofte Hospital
  • University of Copenhagen, Glostrup Hospital
  • University of Oxford
  • Department of Oncology
  • Cancer Research UK Cambridge Institute
  • Bristol Medical School
  • University College London
  • Fred Hutchinson Cancer Research Center
  • University of Washington School of Public Health and Community Medicine
  • Mayo Clinic
  • University Medical Center Ulm and Center of Excellence 'Metabolic Disorders'
  • Brigham and Women's Hospital
  • Pomeranian Medical University in Szczecin
  • University of Utah School of Medicine
  • Edward Hines VA Medical Center
  • German Cancer Research Center
  • Saarland Cancer Registry
  • Moffitt Cancer Center
  • University Hospital “Queen Johanna,”
  • Medical University of Sofia
  • Queensland Institute of Medical Research
  • Inst. Portugues Oncologia
  • LIACC - Artificial Intelligence and Computer Science Laboratory
  • University of Surrey
  • Queensland University of Technology
  • National Cancer Institute (NCI)
  • Washington University School of Medicine in St. Louis
  • Inc.
  • American Cancer Society
  • Harvard T.H. Chan School of Public Health
  • Harvard Medical School
  • University of Hawaii Cancer Center
  • Hellenic Health Foundation, Athens
  • National and Kapodistrian University of Athens
  • Laboratory of Neurodegenerative Diseases
  • National Institute for Public Health and the Environment
  • University Medical Center Utrecht
  • Imperial College London
  • University of Malaya
  • Cell Stress and Survival Unit
  • Centre Léon Bérard
  • Rikshospitalet-Radiumhospitalet HF
  • BioMediTech Finland

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Background: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. Methods: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). Results: We observed no significant association between genetic variants and prostate cancer survival. Conclusions: Common genetic variants with large impact on prostate cancer survival were not observed in this study. Impact: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.

Original languageEnglish
Pages (from-to)1796-1800
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume24
Issue number11
DOIs
StatePublished - Nov 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Genome-wide association study of prostate cancer-specific survival'. Together they form a unique fingerprint.

Cite this